艾昆纬·制药公司的冻结资产-冷链药品[英]

A huge and lingering logistical challenge in delivering vaccines globally during the pandemic has been in scaling up the refrigerated networks that make up part of the global “cold chain” — the uninterrupted process of maintaining end-to-end temperature-controlled conditions from the manufacturing site to the point of care. Cold chain medicines require more energy than their ambient temperature counterparts. If pharmaceutical companies want to live up to their ambitious environmental, social and governance (ESG) targets, they will need to understand current and future trends and work closely with logistics companies to ensure delivery of often live-saving cold chain medicines whilst having their CO2 footprint in mind.